Jagsonpal Pharmaceuticals introduces QueeZy-ER for nausea and vomiting in pregnancy

Jagsonpal Pharmaceuticals Limited, a prominent player in the women’s healthcare sector, has introduced QueeZy-ER, aimed at providing relief from Nausea and Vomiting in Pregnancy (NVP). This innovative solution marks a significant advancement in the management of NVP, leveraging the established efficacy of two key ingredients: Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg, in a state-of-the-art Extended Release (ER) formulation.

At the core of QueeZy-ER’s revolutionary approach is its tablet-in-tablet technology, which ensures the dispersal of a uniform dosage at two distinct intervals from a single dose. This not only allows for 24-hour coverage with just one tablet, as opposed to the traditional 3-4 tablets daily regimen but also significantly reduces the overall therapy cost per day compared to conventional NVP pills. This dual-release formulation provides immediate and prolonged relief, minimizing the need for frequent dosing and thereby enhancing patient adherence and ensuring a more consistent management of symptoms.

The combination of Doxylamine succinate and Pyridoxine hydrochloride encapsulated in QueeZy-ER is notably the only USFDA-approved combination for the treatment of NVP. This highlights the product’s credibility and the rigorous research and development efforts behind its creation. Jagsonpal Pharmaceuticals Limited’s commitment to safety and efficacy is further underscored by the formulation’s reliance on ingredients known for their safety profile in pregnant women, offering a secure and dependable option for managing NVP symptoms.

QueeZy-ER is now accessible in leading pharmacies across India, promising a significant shift in how NVP is treated. Its introduction is expected to resonate positively with healthcare professionals and patients alike, offering a novel and efficient approach to symptom management.

The launch of QueeZy-ER by Jagsonpal Pharmaceuticals Limited is poised to set a new benchmark in the treatment of Nausea and Vomiting in Pregnancy. The product’s innovative delivery mechanism, coupled with the proven efficacy of its active ingredients, positions it as a pivotal development in women’s healthcare. As the market continues to evolve, the demand for such advanced healthcare solutions is anticipated to grow, underscoring the importance of continuous innovation in addressing the unique needs of patients.